Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,226 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hogg D, Hill A, Márquez-Rodas I, Haanen J, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bastholt L, Rizzo JI, Balogh A, Moshyk A, Hodi FS, Wolchok JD. Larkin J, et al. N Engl J Med. 2019 Oct 17;381(16):1535-1546. doi: 10.1056/NEJMoa1910836. Epub 2019 Sep 28. N Engl J Med. 2019. PMID: 31562797 Free article. Clinical Trial.
Malignant melanoma (metastatic).
Larkin J, Gore M. Larkin J, et al. BMJ Clin Evid. 2008 Aug 22;2008:1718. BMJ Clin Evid. 2008. PMID: 19445806 Free PMC article. Review.
Malignant melanoma (metastatic).
Fisher RA, Larkin J. Fisher RA, et al. Among authors: larkin j. BMJ Clin Evid. 2010 Dec 21;2010:1718. BMJ Clin Evid. 2010. PMID: 21418691 Free PMC article. Review.
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA; BRIM-3 Study Group. Chapman PB, et al. Among authors: larkin j. N Engl J Med. 2011 Jun 30;364(26):2507-16. doi: 10.1056/NEJMoa1103782. Epub 2011 Jun 5. N Engl J Med. 2011. PMID: 21639808 Free PMC article. Clinical Trial.
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
Kirkwood JM, Bastholt L, Robert C, Sosman J, Larkin J, Hersey P, Middleton M, Cantarini M, Zazulina V, Kemsley K, Dummer R. Kirkwood JM, et al. Among authors: larkin j. Clin Cancer Res. 2012 Jan 15;18(2):555-67. doi: 10.1158/1078-0432.CCR-11-1491. Epub 2011 Nov 2. Clin Cancer Res. 2012. PMID: 22048237 Free PMC article. Clinical Trial.
Improved survival with MEK inhibition in BRAF-mutated melanoma.
Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D; METRIC Study Group. Flaherty KT, et al. Among authors: larkin jm. N Engl J Med. 2012 Jul 12;367(2):107-14. doi: 10.1056/NEJMoa1203421. Epub 2012 Jun 4. N Engl J Med. 2012. PMID: 22663011 Free article. Clinical Trial.
Ipilimumab activity in advanced uveal melanoma.
Khattak MA, Fisher R, Hughes P, Gore M, Larkin J. Khattak MA, et al. Among authors: larkin j. Melanoma Res. 2013 Feb;23(1):79-81. doi: 10.1097/CMR.0b013e32835b554f. Melanoma Res. 2013. PMID: 23211837
1,226 results